Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sinovac Biotech, a Chinese biopharmaceutical company, has received a purchase order for approximately RMB87 million, of its inactivated hepatitis A vaccine, Healive, from China's Ministry of Public Health.
Subscribe to our email newsletter
The Ministry of Public Health (MOH) order is supported by Sinovac’s newly completed filling and packaging plant that has increased Sinovac’s annual capacity to 20 million doses. Sinovac is currently the sole provider of the hepatitis A vaccine to the MOH for this tender.
Part of the government’s larger scale efforts to improve public health, the hepatitis A vaccination campaign will cover young children from 18 months to 12 years old in 32 cities or counties in nine provinces and is intended to expand the vaccination coverage of hepatitis A throughout China.
Weidong Yin, president and CEO of Sinovac, said: “We are very pleased to have established a public market for our inactivated hepatitis A vaccine, Healive, through this supply agreement with the MOH, as we are focusing our efforts in 2009 on both the public and private pay markets.”